Skip to main content
Erschienen in:

01.11.2012 | Leitthema

T1-High-Risk-Harnblasenkarzinom

Blasenerhalt oder frühe radikale Zystektomie?

verfasst von: Prof. Dr. M.-O. Grimm, T. Gruschwitz, C. Protzel, O.W. Hakenberg

Erschienen in: Die Onkologie | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das T1-High-Risk-Harnblasenkarzinom ist mit einer hohen Rezidiv- und Progressionsrate vergesellschaftet. Darüber hinaus werden mitunter Lymphknotenmetastasen beobachtet. Als Therapieoptionen werden die frühe radikale Zystektomie oder ein blasenerhaltendes Management kontrovers diskutiert. Ein begleitendes Carcinoma in situ sowie der erneute Nachweis eines T1-High-Risk-Tumors in der Nachresektion sind mit einem besonders hohen Progressionsrisiko vergesellschaftet. In diesen Fällen sowie bei multifokalem und/oder sehr großem T1-Tumor ist eine frühe Zystektomie indiziert. Bei unifokalem pT1-Tumor, der in der transurethralen Nachresektion nicht mehr nachweisbar ist, ohne assoziiertes Carcinoma in situ, ist ein primär blasenerhaltendes Vorgehen sinnvoll. Diese beinhaltet eine adjuvante intravesikale BCG- (Bacillus-Calmette-Guérin-)Therapie über mindestens 1 Jahr.
Literatur
1.
Zurück zum Zitat Ali-El-Dein B, Al-Marhoon MS, Abdel-Latif M et al (2011) Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. Urol Ann 3:127–132PubMedCrossRef Ali-El-Dein B, Al-Marhoon MS, Abdel-Latif M et al (2011) Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. Urol Ann 3:127–132PubMedCrossRef
2.
Zurück zum Zitat Alkhateeb SS, Van Rhijn BW, Finelli A et al (2010) Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 84:81–86CrossRef Alkhateeb SS, Van Rhijn BW, Finelli A et al (2010) Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 84:81–86CrossRef
3.
Zurück zum Zitat Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008PubMedCrossRef Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008PubMedCrossRef
4.
Zurück zum Zitat Badalato GM, Gaya JM, Hruby G et al (2012) Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int. doi: 10.1111/j.1464-410X.2012.11116.x. (Epub ahead of print) Badalato GM, Gaya JM, Hruby G et al (2012) Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int. doi: 10.1111/j.1464-410X.2012.11116.x. (Epub ahead of print)
5.
Zurück zum Zitat Brausi MA, Oddens JR, Sylvester RJ et al (2012) Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer. Eur Urol (Suppl) 11:e1050 (Abstract) Brausi MA, Oddens JR, Sylvester RJ et al (2012) Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer. Eur Urol (Suppl) 11:e1050 (Abstract)
6.
Zurück zum Zitat Canter D, Egleston B, Wong YN et al (2011) Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urol Oncol (Epub ahead of print) Canter D, Egleston B, Wong YN et al (2011) Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urol Oncol (Epub ahead of print)
7.
Zurück zum Zitat Chalasani V, Kassouf W, Chin JL et al (2011) Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J 5:83–87PubMedCrossRef Chalasani V, Kassouf W, Chin JL et al (2011) Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J 5:83–87PubMedCrossRef
8.
Zurück zum Zitat De Berardinis E, Busetto GM, Antonini G et al (2011) T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. Int Urol Nephrol 43:1047–1057CrossRef De Berardinis E, Busetto GM, Antonini G et al (2011) T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. Int Urol Nephrol 43:1047–1057CrossRef
9.
Zurück zum Zitat Denzinger S, Fritsche HM, Otto W et al (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152PubMedCrossRef Denzinger S, Fritsche HM, Otto W et al (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152PubMedCrossRef
10.
Zurück zum Zitat Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185–190PubMedCrossRef Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185–190PubMedCrossRef
11.
Zurück zum Zitat Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 60:423–430PubMedCrossRef Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 60:423–430PubMedCrossRef
12.
Zurück zum Zitat Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309PubMedCrossRef Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309PubMedCrossRef
13.
Zurück zum Zitat Grimm MO, Steinhoff C, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437PubMedCrossRef Grimm MO, Steinhoff C, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437PubMedCrossRef
14.
Zurück zum Zitat Hautmann RE, Gschwend JE, Petriconi RC de et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486–492PubMedCrossRef Hautmann RE, Gschwend JE, Petriconi RC de et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486–492PubMedCrossRef
15.
Zurück zum Zitat Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299PubMedCrossRef Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299PubMedCrossRef
16.
Zurück zum Zitat Herr HW, Donat SM, Dalbagni G (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177:75–79PubMedCrossRef Herr HW, Donat SM, Dalbagni G (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177:75–79PubMedCrossRef
17.
Zurück zum Zitat Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70PubMedCrossRef Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70PubMedCrossRef
18.
Zurück zum Zitat Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124–1129PubMedCrossRef Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124–1129PubMedCrossRef
19.
Zurück zum Zitat Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690–696PubMedCrossRef Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690–696PubMedCrossRef
20.
Zurück zum Zitat Malmström PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56:247–256PubMedCrossRef Malmström PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56:247–256PubMedCrossRef
21.
Zurück zum Zitat May M, Bastian PJ, Brookman-May S et al (2011) Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol 45:251–257PubMedCrossRef May M, Bastian PJ, Brookman-May S et al (2011) Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol 45:251–257PubMedCrossRef
22.
Zurück zum Zitat Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus calmette-guérin. Eur Urol 62:118–125PubMedCrossRef Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus calmette-guérin. Eur Urol 62:118–125PubMedCrossRef
23.
Zurück zum Zitat Shahin O, Thalmann GN, Rentsch C et al (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169:96–100PubMedCrossRef Shahin O, Thalmann GN, Rentsch C et al (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169:96–100PubMedCrossRef
24.
Zurück zum Zitat Stein JP, Lieskovsky G, Cote R (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed Stein JP, Lieskovsky G, Cote R (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed
25.
Zurück zum Zitat Sylvester RJ, Meijden AP van der, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970PubMedCrossRef Sylvester RJ, Meijden AP van der, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970PubMedCrossRef
26.
Zurück zum Zitat Sylvester RJ (2011) Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 18:113–120PubMedCrossRef Sylvester RJ (2011) Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 18:113–120PubMedCrossRef
27.
Zurück zum Zitat Thalmann GN, Markwalder R, Shahin O et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75PubMedCrossRef Thalmann GN, Markwalder R, Shahin O et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75PubMedCrossRef
28.
Zurück zum Zitat Thomas F, Rosario DJ, Rubin N et al (2012) The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: Time to change treatment paradigm? Cancer. doi: 10.1002/cncr.27587 (Epub ahead of print) Thomas F, Rosario DJ, Rubin N et al (2012) The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: Time to change treatment paradigm? Cancer. doi: 10.1002/cncr.27587 (Epub ahead of print)
29.
Zurück zum Zitat Bosch S van den, Witjes AJ (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500PubMedCrossRef Bosch S van den, Witjes AJ (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500PubMedCrossRef
Metadaten
Titel
T1-High-Risk-Harnblasenkarzinom
Blasenerhalt oder frühe radikale Zystektomie?
verfasst von
Prof. Dr. M.-O. Grimm
T. Gruschwitz
C. Protzel
O.W. Hakenberg
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 11/2012
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-012-2328-5

Weitere Artikel der Ausgabe 11/2012

Der Onkologe 11/2012 Zur Ausgabe

Journal Club

Pankreaschirurgie

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Schon länger ist bekannt, dass die Aktivität des Immunsystems mit den Jahreszeiten variiert. Auch die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen, wie eine Studie bei fortgeschrittenem nichtkleinzelligem Lungenkarzinom zeigt.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.